Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1999, for OXIS International, Inc. (Note: The filing header identifies the registrant as OXIS International, Inc., despite the request metadata referencing GT Biopharma, Inc.). The company operates in two segments: Health Products and Therapeutic Products Development. During the period, the company sold its therapeutic drug monitoring assay business and closed its French research laboratory to reduce expenses.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1999 |
|---|---|---|
| Total Revenues | $898,000 | $5,055,000 |
| Net Loss | $(1,059,000) | $(4,032,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.13) | $(0.51) |
| Cash and Cash Equivalents (End of Period) | $245,000 | $245,000 |
| Net Cash Used in Operating Activities | Filing text does not provide a clear value for the quarter | $(2,509,000) |
| Total Current Liabilities | $1,963,000 | $1,963,000 |
| Working Capital | $1,209,000 | $1,209,000 |
Material Changes vs. Prior Period
- Revenue: Nine-month revenues increased 32% to $5.055 million, driven by a one-time $911,000 gain from the sale of therapeutic drug monitoring technology and increased sales of research assays. However, instrument sales declined significantly ($931,000 decrease) due to reduced OEM orders.
- Net Loss: The nine-month net loss improved by $1.076 million compared to the prior year, primarily due to reduced R&D and SG&A expenses following the closure of the French lab and cost-cutting measures.
- Liquidity: Cash and cash equivalents plummeted from $2.575 million at year-end 1998 to $245,000 at September 30, 1999. Working capital decreased from $3.03 million to $1.209 million.
- Assets: Total assets decreased from $11.168 million to $5.239 million, reflecting the sale of land, buildings, and technology assets.
Guidance, Outlook, and Risks
- Capital Needs: Management expects to require new revenue sources or additional capital by the end of the first quarter of 2000 to continue operations. Failure to secure funding could force the company to severely curtail or cease operations.
- NASDAQ Delisting Risk: The company received notice from NASDAQ that its stock failed to maintain a $1.00 minimum bid price and its net tangible assets ($3.118 million) fell below the required $4.0 million. The company has until January 18, 2000, to regain compliance or face delisting.
- Operational Restructuring: The company is restructuring therapeutic development operations and seeking corporate partners. Activities in this segment are currently minimal pending funding.
- Year 2000 Compliance: The company believes critical systems are compliant, with upgrade costs under $100,000, though risks remain regarding third-party vendors.
Investor Verification Checklist
- Verify the company's ability to raise capital or generate revenue by Q1 2000 to avoid cessation of operations.
- Confirm the status of the NASDAQ compliance plan to prevent delisting by January 2000.
- Assess the sustainability of revenue streams given the decline in instrument sales and the one-time nature of the technology sale.
- Review the terms of the manufacturing agreement with the purchaser of the therapeutic drug monitoring assets, which expires in Q3 2000.
- Monitor cash burn rate given the current cash balance of only $245,000.